الرئيسية › الورم النقوي المتعدد › كارولاينا الشمالية › Durham
التجارب السريرية لـ الورم النقوي المتعدد في Durham، NC
37 دراسات لـ الورم النقوي المتعدد تبحث عن مشاركين في مواقع داخل وحول Durham (ضمن نطاق 30 ميلًا تقريبًا). افتح الدراسة لمعرفة من يمكنه المشاركة وكيفية التواصل مع فريق الدراسة.
النص الرسمي للدراسة (بالإنجليزية)
تبحث عن مشاركين لدراسة؟ أبرزها في أعلى الصفحة — $99 لمدة 30 يومًا →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
جارٍ التسجيلالمرحلة 3
- Research Site, Chapel Hill · على بُعد 10 ميل
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
جارٍ التسجيلالمرحلة 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · على بُعد 10 ميل
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
جارٍ التسجيلالمرحلة 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
جارٍ التسجيلالمرحلة 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · على بُعد 10 ميل
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
جارٍ التسجيلالمرحلة 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · على بُعد 10 ميل
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
جارٍ التسجيلالمرحلة 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 2
- University of North Carolina Medical Center, Chapel Hill · على بُعد 10 ميل
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
جارٍ التسجيلالمرحلة 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · على بُعد 10 ميل
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
جارٍ التسجيلالمرحلة 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · على بُعد 13 ميل
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
جارٍ التسجيلالمرحلة 1/2
- GSK Investigational Site, Chapel Hill · على بُعد 10 ميل
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
جارٍ التسجيلالمرحلة 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
جارٍ التسجيلالمرحلة 3
- Research Site, Durham
- Research Site, Chapel Hill · على بُعد 10 ميل
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
جارٍ التسجيل
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · على بُعد 10 ميل
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
جارٍ التسجيلالمرحلة 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · على بُعد 10 ميل
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
جارٍ التسجيلالمرحلة 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · على بُعد 10 ميل
Selinexor and Backbone Treatments of Multiple Myeloma Patients
جارٍ التسجيلالمرحلة 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- University of North Carolina /ID# 251203, Chapel Hill · على بُعد 10 ميل
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
جارٍ التسجيلالمرحلة 1
- University of North Carolina at Chapel Hill, Chapel Hill · على بُعد 10 ميل
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
جارٍ التسجيلالمرحلة 2
- University of North Carolina (Data Collection Only), Chapel Hill · على بُعد 10 ميل
Registry of Older Patients With Cancer
جارٍ التسجيلدراسة رصدية
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · على بُعد 10 ميل
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
جارٍ التسجيلالمرحلة 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
جارٍ التسجيلالمرحلة 2
- University of North Carolina, Chapel Hill · على بُعد 10 ميل
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
جارٍ التسجيلالمرحلة 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · على بُعد 10 ميل
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · على بُعد 10 ميل
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
جارٍ التسجيلالمرحلة 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · على بُعد 13 ميل
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
جارٍ التسجيلالمرحلة 1
- University of North Carolina, Chapel Hill · على بُعد 10 ميل
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
جارٍ التسجيلالمرحلة 1
- University of North Carolina, Chapel Hill · على بُعد 10 ميل
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
جارٍ التسجيلالمرحلة 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · على بُعد 10 ميل
Registry for Adults With Plasma Cell Disorders (PCD's)
جارٍ التسجيلدراسة رصدية
- North Carolina Cancer Hospital, Chapel Hill · على بُعد 10 ميل
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
جارٍ التسجيلدراسة رصدية
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · على بُعد 10 ميل
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- Duke University Health System (DUHS), Durham
تجارب الورم النقوي المتعدد في مدن أخرى
- New York City, NY60 دراسات
- Boston, MA42 دراسات
- Atlanta, GA41 دراسات
- Houston, TX38 دراسات
- Nashville, TN32 دراسات
- Denver, CO27 دراسات
- Rochester, MN24 دراسات
- St. Louis, MO24 دراسات
- Columbus, OH24 دراسات
- Baldwin Park, CA23 دراسات
- Chicago, IL22 دراسات
- Seattle, WA22 دراسات
دراسات أخرى في Durham
- سرطان الثدي63 دراسات
- السرطان (جميع الأنواع)58 دراسات
- سرطان الرئة غير صغير الخلايا39 دراسات
- السرطان النقيلي33 دراسات
- ابيضاض الدم النقوي الحاد33 دراسات
- سرطان الرئة32 دراسات
- سرطان البروستاتا32 دراسات
- سرطان القولون والمستقيم28 دراسات
- ابيضاض الدم اللمفاوي المزمن27 دراسات
- سرطان المبيض27 دراسات
- قصور القلب26 دراسات
- سرطان البنكرياس24 دراسات
من ClinicalTrials.gov، البيانات مستخرجة في 05/10/2026. كل دراسة تحدد معايير أهليتها الخاصة؛ فريق الدراسة هو من يحدد من يمكنه المشاركة.